(JNS.org) Israeli pharmaceutical giant Teva has signed a deal with American pharmaceutical company Galena Biopharma to develop and sell the promising breast cancer vaccine NeuVax in Israel, Globes reported.
Galena Biopharma president and CEO Mark Ahn said, "This agreement is the first piece of our global commercialization strategy. Teva is a world-class pharmaceutical company and a major pharmaceutical company in Israel.”
Kaplan Medical Center department of oncology head Dr. Noa Efrat, an investigator for the trial in Israel, said, "We are embarking on a very exciting and innovative venue for the adjuvant treatment of early breast cancer.”
According to Galena Biopharma, NeuVax is vaccine aimed at preventing or delaying the recurrence of breast cancer in cancer survivors. In clinical trials thus far, it has been proven safe and effective, and it is now entering Phase III testing in the U.S.